Legacy sterile injectable products developed prior to the widespread adoption of Quality by Design (QbD) principles are often entered into the product lifecycle with a limited quantitative understanding of process variability. FDA's Process Validation Guidance (2011) recognizes Stage 3 continued process verification (CPV) as a lifecycle activity and introduces Stage 3a heightened monitoring as a mechanism to establish a statistically meaningful baseline prior to routine monitoring (Stage 3b). Published examples describing structured Stage 3a execution for commercial legacy injectables remain limited. This article presents a commercial scale case study describing the design, execution, and outcomes of a Stage 3a monitoring program for a lyophilized injectable product. A risk based, statistically justified sampling strategy was implemented across multiple commercial batches to quantify intra and inter batch variability, evaluate spatial variability within the lyophilizer, and assess time-dependent degradation risks. Variance component analysis, regression analysis, and process capability metrics were applied to both historical and Stage 3a data. Results identified total manufacturing time from API addition through filling as a key contributor to impurity variability and revealed a reproducible shelf specific assay trend. The Stage 3a program enabled conversion of previously assumed controls into measurable and trended parameters and supported development of a data driven Stage 3b monitoring strategy aligned with FDA and ICH lifecycle validation principles. This case study illustrates how Stage 3a can be effectively leveraged to close residual process knowledge gaps for legacy sterile injectable products.
Pazhayattil et al. (2026) studied this question.